FibroBiologics (FBLG) Total Non-Current Liabilities (2022 - 2024)

FibroBiologics (FBLG) has reported Total Non-Current Liabilities for 3 consecutive years, with $13.7 million the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Total Non-Current Liabilities rose 29.76% year-over-year to $13.7 million; the trailing twelve-month figure through Dec 2024 stood at $13.7 million (up 29.76% YoY), and the FY2024 full-year result was $13.7 million, up 29.76% from the prior year.
• Total Non-Current Liabilities grew to $13.7 million in Q4 2024 per FBLG's latest filing, from $4.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $15.3 million in Q1 2024 and bottomed at -$13.9 million in Q2 2023.
• Historically, Total Non-Current Liabilities has averaged $5.3 million across 3 years, with a median of $6.4 million in 2022.
• The widest YoY moves for Total Non-Current Liabilities: up 1484.94% in 2024, down 29.76% in 2024.
• Over 3 years, Total Non-Current Liabilities stood at $6.2 million in 2022, then soared by 69.13% to $10.6 million in 2023, then gained by 29.76% to $13.7 million in 2024.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $13.7 million, $4.8 million, and $6.5 million for Q4 2024, Q3 2024, and Q2 2024 respectively.